BridgeBio Pharma BBIO Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
Based on trailing twelve months.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's return on assets?
- BridgeBio Pharma (BBIO) reported return on assets of -64.8% in Q1 2026.
- How has BridgeBio Pharma's return on assets changed year-over-year?
- BridgeBio Pharma's return on assets increased by 17.1% year-over-year, from -78.2% to -64.8%.
- What is the long-term trend for BridgeBio Pharma's return on assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's return on assets has grown at a 0.9% compound annual growth rate (CAGR), from -75.7% to -79%.
- What does return on assets mean?
- How much profit the company squeezes out of everything it owns.
- How do you interpret return on assets?
- Higher means more productive assets. Unlike ROE, it is unaffected by leverage, so a wide ROE-minus-ROA gap flags a heavily levered balance sheet.
- How does return on assets compare across companies?
- Best compared within an industry — asset intensity varies enormously across sectors. Not meaningful for banks, whose assets are largely financial.